BioMarin’s phase 3 study of pegvaliase meets primary endpoint
The drug, however, did not show enough benefit in related inattention and mood complications. Pegvaliase is being tested against a placebo in patients of Phenylketonuria (PKU) or phenylalanine
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.